Difference between revisions of "Agomelatine-fluvoxamine"
From Psychiatrienet
| Line 2: | Line 2: | ||
| from = agomelatine | | from = agomelatine | ||
| to = fluvoxamine | | to = fluvoxamine | ||
| − | | stop = | + | | stop = {{StopAgomelatine}} |
| − | |||
| − | |||
| start = | | start = | ||
* A wash-out period of one day is necessary. | * A wash-out period of one day is necessary. | ||
| Line 10: | Line 8: | ||
| info = | | info = | ||
* Fluvoxamine stops the metabolism of agomelatine via CYP1A2 and CYP2C9. | * Fluvoxamine stops the metabolism of agomelatine via CYP1A2 and CYP2C9. | ||
| − | + | ||
}} | }} | ||
Revision as of 13:38, 5 March 2010
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
Switch medication from agomelatine to fluvoxamine.[1] [2]
Stop agomelatine - Day 1: Stop agomelatine.
- Agomelatine can be stopped abruptly for every dosage.[3]
Start fluvoxamine- A wash-out period of one day is necessary.
- Start administration of fluvoxamine the next day in a normal dosage of 50 mg/day.
More information- Fluvoxamine stops the metabolism of agomelatine via CYP1A2 and CYP2C9.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
